KIM-1 Biomarker Meta-Analysis for Renal Cell Carcinoma Prognosis and Treatment Response

A systematic review and meta-analysis of eight studies comprising 3002 patients, evaluating the biomarker Kidney injury molecule-1 (KIM-1) in renal cell carcinoma. The work, authored by Toni Febriyanto and last updated in May 2026, quantifies the association between baseline KIM-1 levels and survival outcomes, as well as post-treatment KIM-1 changes and therapy response. It pools hazard ratios from studies sourced from PubMed, Embase, and the Cochrane Library up to November 2025.

Use Cases

• Validate KIM-1 as a prognostic biomarker based on pooled hazard ratios for overall survival and disease-free survival.
• Assess KIM-1's predictive value for systemic therapy response based on reported associations between post-treatment declines and improved progression-free survival.
• Inform the design of clinical trials for renal cell carcinoma by leveraging the quantified risk associations from the meta-analysis.

Strengths

• Analysis is based on eight studies with a combined sample of 3002 patients.
• Reports specific pooled hazard ratios with confidence intervals, such as HR 1.44 for overall survival.
• The work follows a systematic review methodology with searches across multiple databases.

Limitations

• The dataset is a 545.1 KB document (PDF/JPG), not a structured data file; column-level documentation is absent.
• Row count for underlying study data is unknown, which may limit suitability assessment for secondary analysis.
• The description notes 'lower certainty' and a need for further validation of the biomarker's value.

Provenance

Source

figshare

Collection Method

Systematic review and meta-analysis of studies from PubMed, Embase, and the Cochrane Library.

Time Range

Literature search conducted through November 2025.

Freshness

Last updated 2026-05-04 09:30:02